Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
Holding BMY?
Track your performance easily
BMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.35 - $56.80
Previous Close$54.14
Volume9.22M
Average Volume (3M)10.64M
Market Cap
$110.96B
Enterprise Value$152.68B
Total Cash (Recent Filing)$8.09B
Total Debt (Recent Filing)$49.75B
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Feb 06, 2025EPS Estimate
$1.47Last Dividend Ex-Date
Oct 04, 2024Dividend Yield4.39%
Share Statistics
EPS (TTM)-3.60
Shares Outstanding2,028,176,674
10 Day Avg. Volume11,130,357
30 Day Avg. Volume10,636,712
Standard Deviation0.06
R-Squared0.13
Alpha-0.00074
Financial Highlights & Ratios
Price to Book (P/B)6.41
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)5.00
P/FCF Ratio5.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.22
Enterprise Value/Gross Profit4.45
Enterprise Value/Ebitda33.59
Forecast
1Y Price Target
$54.00Price Target Upside-0.26% Downside
Rating ConsensusHold
Number of Analyst Covering15
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Clinical Trial UpdateBristol-Myers Squibb disclosed an encouraging clinical trial update on milvexian, its novel Factor XIa blood thinner, which positively impacts investor perception.
Earnings PerformanceBristol-Myers Squibb reported a solid quarter with both topline and bottomline beats, driven by higher revenue, higher gross margin, and lower financial costs.
Product GrowthBreyanzi exceeded expectations with growth primarily due to pent-up demand from new indications and expanded manufacturing, contributing to strong performance in cell therapy.
Bears Say
Competitive PressuresForthcoming competitor data from AbbVie's emraclidine will be crucial in determining which agent will ultimately assume a leadership position.
Product Launch ChallengesSotyktu, Zeposia, and Krazati launches remain underwhelming.
Revenue And Margin CompressionThe company will face meaningful revenue and margin compression in the '26-'30 period, which does not appear to be reflected at current valuation.
---
Ownership Overview
0.07% Insiders
21.56% Mutual Funds
6.88% Other Institutional Investors
47.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $56.80 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 06, 2025 which is in 88 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 31, 2024. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.494 by $0.306.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 4.39%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.47.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,028,176,600 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.8 in its last earnings report, beating expectations of $1.494. Following the earnings report the stock price went up 5.906%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 976M.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$54.00 (-0.26% Downside)
$54.00 (-0.26% Downside)
Blogger Sentiment
Bullish
BMY Sentiment 98%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.50%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
2.64%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q3 2024
0:00 / 0:00
---
BMY Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$54.00
▼(-0.26% Downside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
14/20 ratings generated profit
1 Year Average Return
+6.62%
reiterated a sell rating 9 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +6.62% per trade.
---